Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSymphony Env. Regulatory News (SYM)

Share Price Information for Symphony Env. (SYM)

Share Price is delayed by 15 minutes
Get Live Data
6.75    0.00 (0.00%)
Bid:
6.00
Ask:
7.50
Spread: 1.50 (25.00%)
Market Cap: £15.95m
SYM Live PriceLast checked at - London Stock Exchange

Intraday Symphony Env. Share Chart

HSAC report

7 Apr 2026 07:00

RNS Number : 4271Z
Symphony Environmental Tech. PLC
07 April 2026
 

 

This is a Reach (i.e. non-regulatory) announcement and the information contained is not considered to be material or to have a significant impact on management's expectations of the Company's performance.

Symphony Environmental Technologies Plc

("Symphony" or the "Company")

Analysis of UK Government Report Confirms d2w® Biodegradable Plastic Is Proven, Tested and Safe

Symphony Environmental Technologies Plc ("Symphony" or "the Company") a global leader in "smarter, safer, and sustainable" plastic and rubber technologies, is delighted to announce that a comprehensive scientific analysis confirms that oxo‑biodegradable plastic technology is a proven, well‑established solution, supported by decades of independent testing and real‑world use.

The analysis demonstrates that this technology is not experimental, novel or untested, but is based on over 50 years of polymer science, more than 30 years of global commercial use, and extensive testing by leading scientists and internationally accredited laboratories.

The evidence shows that d2w® plastics are specifically designed to degrade safely in the open environment and then biodegrade without leaving behind persistent microplastics, while remaining compatible with existing recycling systems where collection occurs.

The Biodegradable Plastics Association (BPA) has today published its response https://www.biodeg.org/wp-content/uploads/2026/03/BPA-RESPONSE-31.3.26.pdf to the UK Government's 2025 HSAC Report This BPA paper demonstrates conclusively that there is no technical, scientific, or safety‑based reason to prohibit or discourage the use of oxo‑biodegradable polyethylene (PE) and polypropylene (PP), provided they are correctly manufactured, and assessed using the appropriate international standards.

First, the paper establishes that oxo‑biodegradable plastic is not an experimental or unproven technology. It has been in continuous scientific development for over fifty years, and has been in commercial use for 20 years. It was invented by leading polymer scientists, and is supported by a coherent and well‑understood mechanism: - controlled oxidative chain scission followed by biological assimilation.

It is fundamentally different from composting and mere physical fragmentation, and it does not leave microplastics. This two‑stage process is recognised and understood in the international technical literature and Standards, and there is no credible dispute in polymer science that oxidation reduces molecular weight and that sufficiently oxidised polyolefins are biodegradable. This has been demonstrated in the real world, notably by the Oxomar project.

Second, the paper shows that the correct technical benchmark already exists. ASTM D6954 (and aligned national standards such as BS 8472) was specifically written to assess plastics intended to degrade and then biodegrade in the open environment. These standards define what must be measured, how it must be measured, and what constitutes pass or fail for degradation, biodegradation, and environmental safety. The existence and long‑standing use of these standards means there is no technical gap requiring new methodologies, speculative testing regimes, or ad‑hoc academic proxies.

Third, the paper demonstrates that independent, ISO 17025‑accredited testing has already proven performance. The Intertek test reports cited show high levels of biodegradation of oxo‑biodegradable PE and PP, compliance with ecotoxicity requirements, and-critically-the absence of persistent microplastics. Molecular‑weight measurements confirm that any residual particles no longer behave as plastics. From a regulatory and technical standpoint, this directly addresses the principal concerns typically raised: persistence, toxicity, and microplastic formation.

Fourth, the paper shows that claims of technical failure are driven by inappropriate test protocols not by deficiencies in the technology. See https://www.biodeg.org/wp-content/uploads/2026/03/BPA-Dossier-with-links-10-2-26-optimised-V13-31-Mar-26.pdf Many academic papers which have passed peer-review, either test the wrong materials, fail to characterise samples, use incorrect standards (e.g. composting standards), terminate tests prematurely, or expose materials to conditions for which they were not designed (such as burial or submersion). The paper demonstrates that such studies cannot be used to draw valid conclusions about the performance of properly made oxo‑biodegradable plastics.

Fifth, the paper addresses geographical variability directly and shows that variation in degradation rate is not technical failure. Like all chemical and biological processes, oxo‑biodegradation proceeds more slowly in cooler or lower‑UV conditions, but there is no evidence that the process fails, stops, or reverses. This behaviour is entirely consistent with established kinetics.

No regulatory principle requires uniform degradation speed across climates, only predictable and demonstrable performance relative to conventional plastics-which oxo‑biodegradable materials are intended to replace.

Sixth, the paper confirms that oxo‑biodegradable plastic is compatible with recycling, unlike some alternative materials that are nevertheless permitted on the market. There is therefore no technical incompatibility with circular‑economy objectives for collected material, while still providing a clear environmental advantage for plastic that inevitably escapes collection.

Taken together, the evidence shows that oxo‑biodegradable plastic such as d2w®:

· functions as designed;

· is supported by established polymer science and long user;

· is testable and verifiable using recognised standards;

· has been independently proven to biodegrade without creating persistent microplastics or ecotoxicity; and

· performs better than conventional plastic if it gets into the open environment, which is the only context in which its designed function is relevant.

Accordingly, this paper demonstrates that there is no technical justification for prohibition, restriction, or regulatory exclusion of oxo‑biodegradable plastics.

 

For further information, please contact:

Symphony Environmental Technologies Plc

Tel: +44 (0)20 8207 5900

Website: https://www.symphonyenvironmental.com

 

NOTES TO EDITORS

Symphony also supplies a range of plastic technologies under its d2p (designed to protect) brand www.d2p.net to provide protection against insects, viruses, bacteria, fungi, rodents, odours, and fire. It has also introduced a new product under its NbR brand https://www.symphonyenvironmental.com/natural-biodegradable-resin/ to reduce the amount of fossil-derived material in plastic products.

Symphony has a diverse and growing customer-base and has established itself as an international business with over 70 distributors around the world. Products made with Symphony's plastic technologies are now available in nearly 100 countries and in many different product applications. Symphony itself is certified according to ISO9001 and ISO14001.

Symphony participates in the Committee work of the British Standards Institute (BSI), the American Standards Organisation (ASTM), the European Standards Organisation (CEN), and the International Standards Organisation (ISO).

Further information on the Group can be found at www.symphonyenvironmental.com 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUNURRNUUSRUR
Date   Source Headline
28th Dec 200711:06 amRNSResult of EGM
21st Dec 20073:38 pmRNSHolding(s) in Company
19th Dec 200712:41 pmRNSHolding(s) in Company
12th Dec 20074:09 pmRNSHolding(s) in Company
11th Dec 20073:25 pmRNSIssue of Equity
10th Dec 20074:34 pmRNSHolding(s) in Company-Replace
5th Dec 20074:58 pmRNSHolding(s) in Company
4th Dec 20077:01 amRNSIssue of Equity & EGM Notice
3rd Dec 20074:48 pmRNSIssue of Equity & EGM Notice
26th Nov 20073:29 pmRNSTotal Voting Rights
26th Nov 200711:20 amRNSIssue of Options
2nd Oct 20074:16 pmRNSChange of Adviser
28th Sep 20073:50 pmRNSAdditional Listing - Amended
27th Sep 20078:00 amRNSAdditional Listing
27th Sep 20077:01 amRNSInterim Results
17th Aug 20073:37 pmRNSAIM Rule 26
3rd Aug 20077:01 amRNSAppointment of Director
27th Jul 20079:38 amRNSAGM resolutions
27th Jul 20079:00 amRNSAGM Statement
18th Jul 20077:00 amRNSTrading on PLUS
29th Jun 20077:00 amRNSReport & Accounts/AGM Notice
28th Jun 20077:01 amRNS2007 Preliminary Results
30th May 20071:40 pmRNSBusiness Update
9th May 20072:02 pmRNSAdditional Listing
30th Apr 20074:37 pmRNSBus Update & Board Change
7th Mar 20073:59 pmRNSHolding(s) in Company
2nd Mar 200710:51 amRNSHolding(s) in Company
28th Feb 20077:03 amRNSUpdate on placing
27th Feb 20079:57 amRNSResult of EGM
22nd Feb 200710:01 amRNSTrading Update
6th Feb 20077:00 amRNSNotice of EGM
19th Dec 200611:02 amRNSTotal Voting Rights
15th Dec 20067:58 amRNSTrading Statement
13th Nov 20062:16 pmRNSBoard Appointment
13th Oct 20069:28 amRNSTrading Update
25th Sep 20067:01 amRNSInterim Results
20th Sep 200611:07 amRNSNotice of Results
29th Aug 20068:59 amRNSDirectorate Change
21st Aug 20067:00 amRNSSales Agreement
14th Jul 200611:54 amRNSResult of AGM
14th Jul 20069:49 amRNSAGM Statement
21st Jun 200610:04 amRNSNotice of AGM
15th Jun 20067:02 amRNSStrategic Update
22nd May 20067:00 amRNSCaribbean Sales Update
27th Apr 20067:00 amRNSPreliminary Results
24th Apr 20067:01 amRNSNotice of Results (Revised)
4th Apr 20062:12 pmRNSNotice of Results
30th Jan 200611:41 amRNSCourt Award
16th Jan 20068:44 amRNSDirector Shareholding
19th Dec 20053:26 pmRNSCourt Victory

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.